Last reviewed · How we verify
Nordilet®
Nordilet is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion.
Nordilet is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion. Used for Type 2 diabetes.
At a glance
| Generic name | Nordilet® |
|---|---|
| Also known as | recombinant human growth hormone (Nordilet®) |
| Sponsor | Cinnagen |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DPP-4 inhibitors like Nordilet work by blocking the action of DPP-4, an enzyme that breaks down incretin hormones. This leads to increased levels of incretin hormones, which in turn stimulate the release of insulin from the pancreas in a glucose-dependent manner, thereby lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Nausea
- Diarrhea
Key clinical trials
- Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency (PHASE3)
- Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nordilet® CI brief — competitive landscape report
- Nordilet® updates RSS · CI watch RSS
- Cinnagen portfolio CI